| Document |
Document Title |
|
WO/2023/148524A1 |
Adipose tissue lipoaspirated or removed from the body, containing mesenchymal stem cells, obtained with a method for promoting the anti- inflammatory properties and for improving the repairing capability, comprising a step of mechanical ...
|
|
WO/2022/127066A9 |
The present invention relates to the technical field of biology, and particularly relates to a bispecific antibody for specifically neutralizing a TGF-β signal of a helper T cell. The bispecific antibody at least comprises a first prote...
|
|
WO/2023/149700A1 |
The present invention provides a pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of allopurinol, febuxostat or a pharmaceutically acceptable salt thereof for the prevention or treatment of...
|
|
WO/2023/149794A1 |
The invention relates to biotechnology and can be used for treating benign prostatic hyperplasia related to chronic prostatitis. A method for producing an active compound from Lymantria dispar larvae includes growing insects under contro...
|
|
WO/2023/145959A1 |
A medicine for treating or preventing interstitial lung disease and the disease or symptoms associated with systemic scleroderma in a subject, said medicine containing, as an active ingredient, 1-\{2-[(3S,4R)-1-\{[(3R,4R)-1-cyclopentyl-3...
|
|
WO/2023/146512A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating diseases. Specific diseases include those that are mediated by YAP/TAZ or those that are modulated by the interaction be...
|
|
WO/2023/143293A1 |
A pharmaceutically acceptable salt type and crystal form of a compound as represented by the following formula (I), and a preparation method of the compound and an application thereof.
|
|
WO/2023/143563A1 |
The present application relates to an IgA protease truncation, a fusion protein comprising the IgA protease truncation (e.g., a fusion protein comprising the IgA protease truncation and an Fc), and use thereof in treating an IgA depositi...
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2023/145735A1 |
Provided is a new therapy/prevention for aging-related disorders including sarcopenia. The present invention pertains to a pharmaceutical composition that contains an expectorant (examples thereof include compounds, or pharmaceutically a...
|
|
WO/2023/145486A1 |
One embodiment of the present invention provides a method for producing a stable fesoterodine fumarate-containing formulation. In said method the generation of related substances is suppressed by using an easy-to-handle general-purpose a...
|
|
WO/2023/143401A1 |
The present invention relates to a compound having inhibitory activity for the lectin pathway of complement, a preparation method therefor, and an application thereof. Specifically, the present invention relates to a compound as represen...
|
|
WO/2023/143573A1 |
A use of a bismuth-containing compound in preparation of a medicament which is used for treating and/or relieving a disease or condition associated with electrolyte imbalance in a subject. The disease or condition associated with the ele...
|
|
WO/2023/144341A1 |
The present invention relates to methods and compositions for preventing and/or treating pyelonephritis and/or urosepsis.
|
|
WO/2023/146511A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating diseases. Specific diseases include those that are mediated by YAP/TAZ or those that are modulated by the interaction be...
|
|
WO/2023/145873A1 |
The present invention pertains to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (The definitions of R1, R2, L, m and n in formula (I) are stated in the specification.)
|
|
WO/2023/142801A1 |
The present invention provides a use of a secreted glycoprotein in inhibiting the activity of a bone morphogenic protein. It has been found in the present invention that when omentin-1 is used in inhibiting a bone morphogenic protein, no...
|
|
WO/2023/146437A1 |
The invention relates to the field of pharmacy and medicine, specifically to pharmaceutical compositions of anti-TRBV9 antibody. The invention further relates to the use of said compositions for treating a disease or disorder mediated by...
|
|
WO/2023/140355A1 |
[Problem] Provided is a cancer treatment drug that suppresses the proliferation of cancer cells. [Solution] This cancer treatment drug contains a compound represented by general formula (1) or a pharmaceutically acceptable salt thereof.
|
|
WO/2023/138478A1 |
Disclosed are a solution type nasal spray containing 3-[(2-cyclopentyl-2-hydroxy-2-phenyl)ethoxy]-1-(3-phenoxypro
pyl)-1-azabicyclo[2,2,2]octonium salt or a derivative thereof, and a preparation method therefor. The components of the sol...
|
|
WO/2023/140350A1 |
The present invention provides a pharmaceutical composition for suppressing organ fibrosis, characterized by having an angiotensin II receptor antagonist as an active ingredient, and being administered at a dosage of 0.2 times or less th...
|
|
WO/2023/137885A1 |
Disclosed in the present invention are a compound having pyridoimidazole as the parent nucleus, and a preparation method for and a use of the compound. The compound having pyridoimidazole as the parent nucleus provided by the present inv...
|
|
WO/2023/139285A1 |
The present invention provides for a method of treatment of IgA nephropathy, which method comprises: (i) Identifying a pharmaceutically acceptable composition intended to treat IgA nephropathy comprising budesonide and one or more pharma...
|
|
WO/2023/137941A1 |
A nucleic acid aptamer and a use thereof. The nucleic acid aptamer is a nucleic acid aptamer that can specifically recognize bladder tumor cells and can internalize into the bladder tumor cells. The nucleic acid aptamer has good specific...
|
|
WO/2023/138147A1 |
The present invention relates to the field of medicinal chemistry. Disclosed are a triptolide prodrug, a preparation method therefor and a pharmaceutical use thereof. The preparation steps are: 1, making triptolide react with acyl chlori...
|
|
WO/2023/135207A1 |
The present invention relates to a pharmaceutical combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, prodrug thereof or a metabolite thereof with a S1P receptor modulator or a pharmaceutically accepta...
|
|
WO/2023/134206A1 |
Provided is a use of Bacteroides fragilis and/or a zwitterionic capsular polysaccharide thereof in the preparation of a drug for preventing and treating genitourinary system cancer. Bacteroides fragilis, especially Bacteroides fragilis Z...
|
|
WO/2023/134673A1 |
A high-selectivity KCNQ4 potassium channel agonist of formula I, a preparation method therefor and the use thereof. The compound further improves the KCNQ4 agonistic activity, and is still free of KCNQ2 agonistic activity, thus having ex...
|
|
WO/2023/133607A1 |
A composition comprising: i. at least one chemokine receptor 2 (CCR2) pathway inhibitor or a pharmaceutically acceptable salt thereof, in particular repagermanium or propagermanium; ii. a diluent in a concentration from 30 to 70 % w/w; i...
|
|
WO/2023/134688A1 |
A salt of a ROCK inhibitor, a crystal form of the salt, a composition, and a pharmaceutical use. The salt and the crystal form of the salt are an acid addition salt of a compound I and any acid in the following and a crystal form thereof...
|
|
WO/2023/133982A1 |
A composition which can not only treat chronic inflammation of prostate and calcified spots of prostate, but also improve male function decline caused by these two causes is disclosed. The composition is a health care product composed of...
|
|
WO/2023/136698A1 |
The present invention relates to a biguanide composition in which lupus-casuing B cells and an immunosuppressant having an antibody modulation effect are combined. In the present invention, it has been identified that when a novel compou...
|
|
WO/2023/135532A1 |
The invention concerns a compound of formula (I) or pharmaceutically acceptable salts or hydrates thereof: (I) wherein R represents a 6-membered aryl or heteroaryl group or a 5-membered heteroaryl group, optionally substituted with at le...
|
|
WO/2023/135533A1 |
The invention concerns a compound of formula (I) or pharmaceutically acceptable salts or hydrates thereof: Formula (I) wherein R is chosen from • - phenyl, a 6-membered heteroaryl group, cyclohexyl, a 5- membered heteroaryl group; • ...
|
|
WO/2023/133353A1 |
The present invention provides methods in which early season vigor or canopy formation are stimulated in cereal plants via application of a fenclorim seed treatment. Methods for planting fenclorim-treated seeds at a lower than recommende...
|
|
WO/2023/132369A1 |
Provided is a compound able to activate Nrf2 and represented by formula (1), a salt thereof, or a solvate of these. Formula (1) (In the formula, Xa1 is CRa1 or N, Xa3 is CRa3 or N, Ra1, Ra2, and Ra3 are each independently selected from...
|
|
WO/2023/133217A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2023/133089A1 |
Provided herein are lipid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions ther...
|
|
WO/2023/131017A1 |
Disclosed in the present invention are a crystal form of a fused ring derivative, and a preparation method therefor and the use thereof. The crystal form I of the compound as represented by formula (A) of the present invention has high p...
|
|
WO/2023/123063A1 |
Provided herein are pharmaceutical compositions comprising therapeutic agent (s) and functional excipients that can enable oral absorption of small molecules and/or large molecules. Also provided herein are methods of preparing the pharm...
|
|
WO/2023/127872A1 |
Provided is a method for producing a transplant material that allows a foreign substance to be injected easily into an organ removed from an animal body. Also provided is a transplant material that undergoes reduced damage despite a fore...
|
|
WO/2023/127853A1 |
Provided is a compound represented by formula (1) or a pharmaceutically acceptable salt thereof (in formula (1), Ar is formula (Ar1) or (Ar2), and in these formulas, R1 and R2 each independently denote an alkyl, a haloalkyl, or a halogen...
|
|
WO/2023/125536A1 |
Provided in the present disclosure is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound has a VEGF inhibitory effect, and can be used for preventing and treating diseases or conditions r...
|
|
WO/2023/128906A1 |
The present invention relates to pharmaceutical composition comprising propiverine or a pharmaceutically acceptable salt thereof is in the sustained release coated with enteric coating layer comprising pH modifying agent to reduce drug r...
|
|
WO/2023/127883A1 |
The present invention provides a compound indicated by general formula (1) and having mPGES-1 inhibitory activity, a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, R1 and R2 each independently indicate hy...
|
|
WO/2023/122656A1 |
The present disclosure provides methods of treating a subject having a kidney disease or at risk of developing a kidney disease by administering an Angiopoietin Like 3 (ANGPTL3) inhibitor, and methods of identifying subjects having an in...
|
|
WO/2023/118092A1 |
The present invention relates to substituted pyrazolo[l,5-a]pyridine-[3,2-e]pyrimidines compounds of formula (I) wherein X, R1, and R2 are as defined in the claims, methods of preparing said compounds, pharmaceutical compositions and com...
|
|
WO/2023/117659A1 |
The present disclosure generally relates to methods and compositions comprising urolithin that treat or prevent a disease or condition associated with muscle decline and/or a kidney dysfunction. Moreover, methods and compositions compris...
|
|
WO/2023/122433A1 |
The present disclosure relates to gene editing systems and/or compositions comprising RNA guides targeting HAO1 and RNA guides targeting LDHA. Also provide herein are methods of using the gene editing system for introducing edits to the ...
|
|
WO/2023/118968A2 |
Disclosed herein are methods of detecting xanthine oxidase expression in polycystic kidney disease, or methods of delaying the onset or treating polycystic kidney disease, or both. The inventors have made the remarkable discovery that ab...
|
